Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | MMP1 | P03956 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091233 | 0.95 | PDE4B (0.73) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL7864057 | 0.95 | PDE4B (0.73) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL16552644 | 0.92 | MMP1 (0.76) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL99448 | 0.89 | PDE4B (1.00) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL2413943 | 0.89 | PDE4B (0.93) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL4483889 | 0.89 | NPC1 (0.77) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL6931569 | 0.87 | RAB9A (0.65) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL8347297 | 0.87 | PDE4B (0.63) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL3383941 | 0.87 | PDE4B (0.90) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL3104200 | 0.87 | PDE4B (0.90) | PDE4BCYP1A2ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| WO-2017063910-A1 | AGONISTS OF THE CHEMOKINE RECEPTOR CXCR3 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2017-04-20 | — | — | WO | claimed |
| EP-3156398-A1 | AGONISTS OF THE CHEMOKINE RECEPTOR CXCR3 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2017-04-19 | — | — | EP | claimed |
| CN-106431914-A | Synthetic method for pyridazinone drug intermediate 4-(4-methoxyphenyl)-4-oxobutanoic acid | 厦门安普顿信息科技有限公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| EP-1745004-B1 | ARYL KETONE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-05-18 | — | — | EP | claimed |
| CN-105541599-A | Synthetic method for drug intermediate 4-p-methoxyphenyl-4-ketobutyric acid of pyridazinone | CHENGDU CARDIFF SCIENCE AND TECH CO LTD | 2016-05-04 | — | — | CN | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-9035085-B2 | Aryl ketone compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | claimed |
| EP-0912467-B1 | ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE | RHODIA CHIMIE SA (FR) | 2002-04-24 | — | — | EP | claimed |
| US-5641811-A | USING A 3-(SUBSTITUTED BENZOYLPROPIONIC ACID AS A TASTAND TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE; FOODS, DRUGS; SUBSTITUTES | BIORESEARCH INC. (US) | 1997-06-24 | — | — | US | claimed |
| US-5631038-A | COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-05-20 | — | — | US | claimed |
| EP-0727151-A2 | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH, INC. (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0727150-A2 | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH, INC. (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0661932-A4 | SPECIFIC EATABLE TASTE MODIFIERS. | BIORESEARCH INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0661932-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1993010677-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| EP-0156317-A2 | Foodstuffs containing sweetness inhibiting agents and process for inhibiting the sweetness perception of a foodstuff | GENERAL FOODS CORPORATION (US) | 1985-10-02 | — | — | EP | claimed |
| US-4544565-A | ARYLALKYLKETONES | GENERAL FOODS CORPORATION (US) | 1985-10-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | PDE4B 2823/4885CYP1A2 1899/4885ALDH1A1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.